Novavax opened lower at $9.70, compared with its previous close of $9.98. In the last trading session, the stock traded between $9.16 and $9.74. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Novavax is now worth
$ 5.17
Resulting in a loss of
$ 94.83 (94.83%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-1.22 (-12.24%)
Day High
$9.74
Day Low
$9.16
Day Open
$9.70
Prev Close
$9.98
Volume
62,73,616
1W Return
-17.86%
1M Return
-30.84%
3M Return
10.23%
6M Return
-7.81%
1Y Return
17.72%
Market Cap ($ Mn)
1,445
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
62.96%
EPS (TTM)
$-0.19
1 Week
-17.86%
1 Month
-30.84%
3 Months
10.23%
6 Months
-7.81%
9 Months
-2.36%
B. Riley reiterates Buy on Novavax, lowers price target to $16
B. Riley Securities reiterated a Buy rating on Novavax. Analyst Mayank Mamtani lowered the price target to $16. The previous price target was set at $18.
6 days agoShah Capital sells $32.6 million in Novavax shares, ends activist push
Shah Capital sold 2.87 million Novavax shares worth approximately $32.6 million at an average price of $11.3486 each. The firm ended its activist campaign and shifted to a family office structure, retaining a 6.46% stake in Novavax. Shah Capital previously held up to 9% of the company and urged a sale due to poor vaccine rollout performance.
24 days agoCitigroup raises Novavax price target to $8, maintains sell rating
Citigroup raised Novavax price target to $8. Previous price target was set at $7. Analyst Geoff Meacham maintains Sell rating.
28 days agoNovavax Q2 revenue falls to $57 million as net loss hits $53 million
Total revenue fell to $57 million in Q2 2026 from $239 million in Q2 2025 due to absence of prior-year one-time milestones. Net loss of $53 million recorded; cash and accounts receivable stood at $743 million. Product sales grew 76% YoY to $19 million driven by Matrix-M adjuvant demand from Takeda and Serum Institute. Full-year 2026 adjusted revenue guidance raised to $235-$275 million; combined GAAP R&D and SG&A guidance improved to $390 million midpoint.
1mo agoVaccine stocks trend as Russia plague scare and Vaxcyte raise drive moves
Vaccine stocks trended after-hours following a suspected pneumonic plague case in Siberia. Novavax shares jumped 20.08% in regular trading due to a short squeeze involving 30.43% of float. Vaxcyte announced a $1 billion capital raise to fund VAX-31 vaccine trials and manufacturing. Moderna gained 6.95% in regular hours before rising slightly in after-hours trading.
1mo agoNovavax stock rises 6.2% after FDA approves updated 2026-2027 vaccine
Novavax shares rose 6.19% to $9.95 after FDA approved updated 2026-2027 COVID vaccine. Q2 revenue reached $56.7 million, up 76% YoY, driven by Matrix-M adjuvant demand. Full-year 2026 revenue guidance raised to $235 million-$275 million range. Partners Sanofi and Takeda secured approvals for XFG-adapted Nuvaxovid formulation. Retail speculation links Matrix-M platform to potential oncology applications.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Novavax is now worth
$ 5.17
Resulting in a loss of
$ 94.83 (94.83%)
Note: Past profits do not guarantee future returns.
